Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors

Abstract Background Neutralizing factor VIII (FVIII) antibodies are a major complication in hemophilia A. Antihemophilic factor VIII (recombinant), porcine sequence (rpFVIII; susoctocog alfa; Baxalta US Inc., a Takeda company) has low cross‐reactivity to anti‐human FVIII antibodies and can provide f...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Claude Négrier, Johannes Oldenburg, Gili Kenet, Shannon L. Meeks, Jean‐Claude Bordet, Jens Müller, Sandra Le Quellec, Peter L. Turecek, Nikola Tripkovic, Yesim Dargaud
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2022-05-01
Schriftenreihe:	Research and Practice in Thrombosis and Haemostasis
Schlagworte:	factor VIII inhibitor hemophilia A porcine factor VIII recombinant thrombin
Online-Zugang:	https://doi.org/10.1002/rth2.12731
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!